Kinnate Biopharma Inc.
DelistedCIK 1797768fmd_1KHT3X0T3TPVERJGYPCQQH2GK5Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Dec 31, 2023, 16 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|
| Research and development | 29 | 67 | 88 | 91 |
| Total operating expenses | 36 | 90 | 119 | 121 |
| Operating income | (36) | (90) | (119) | (121) |
| Other non-operating income (expense) | 0 | 0 | 2 | 9 |
| Income tax expense | 0 | 0 | 0 | 0 |
| Net income | (36) | (90) | (116) | (113) |